Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by NotinKansason May 31, 2023 7:30am
199 Views
Post# 35471801

RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial StatementsPandora, there is indeed some chronology in the plot as obviously the patients listed as having had their 450 days assessment have been longer in the trial than those that are still awaiting certain assessments. But within the cohorts, patients are not sorted chronologically, but based on the quality of their response: the better responses on top, the poor responses at the bottom. The first 12 undertreated are in the 450 days cohort, but most will be in the bottom half of that cohort.

Take a look for instance at the patient on line 38 from the swimmer plot presented in the press release of 10 May. He/she was CR at 90, 180, 270 and 360 days. He/she has received their 450 days assessment since then, which must have been CR again (in today’s plot there are neither patients with only 4 assessments, nor patients with 4 CRs followed by either an IR or NR, but we do have two new patients who are CR from 90 through 450 days). In today’s plot, this patient now ranks among the upper 13, it’s not on line 38 anymore. And that goes for all patients: they don’t stick on the same line number from plot to plot, but they move dynamically depending on how their responses rate compared to other patients.
<< Previous
Bullboard Posts
Next >>